PRTG — Portage Biotech Income Statement
0.000.00%
Last trade - 00:00- $13.90m
- $11.47m
- 44
- 35
- 79
- 52
Annual income statement for Portage Biotech, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
C2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 6.01 | 12.3 | 15.6 | 125 | 101 |
| Operating Profit | -6.01 | -12.3 | -15.6 | -125 | -101 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -6.51 | -14.9 | -14.8 | -123 | -85.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.25 | -17.2 | -19.2 | -105 | -75.4 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.33 | -15.8 | -16.9 | -105 | -75.3 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.33 | -15.8 | -16.9 | -105 | -75.3 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.7 | -27.2 | -25.8 | -16.5 | -1.38 |